- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06273436
Healing, Equity, Advocacy and Respect for Mamas (HEAR4Mamas)
Comparing Standard of Care Versus a Technology-Based Approach To Reduce Postpartum Emergency Department Visits
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Constance Guille, MD
- Phone Number: 843-792-6489
- Email: guille@musc.edu
Study Contact Backup
- Name: Ellen H Gomez, MA
- Phone Number: 8439985635
- Email: gomezel@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- Constance Guille, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria for Postpartum Women
- Postpartum woman within approximately 2 weeks of delivering a baby of gestational age ≥ 26 weeks in South Carolina.
- Aged 16-49 years old.
- Insured by Medicaid.
Exclusion Criteria for Postpartum Women
- Plans to relocate outside of SC anytime during the postpartum year.
- Plans to discontinue Medicaid health insurance during the postpartum year.
- Speaks a language other than English or Spanish.
- Incarcerated/pending incarceration during peripartum period.
- Currently institutionalized.
- Enrolled in current MUSC study funded by PCORI (#Pro00123833)
- Does not have and/or does not wish to use their personal cell phone for the study.
Inclusion Criteria for Obstetric Providers and Hospital Administrators
- OB provider working at a delivery hospital in SC and directly involved in the care of postpartum women; or hospital administrator working in a delivery hospital in SC and job responsibilities relate to the postpartum unit.
Exclusion Criteria for Obstetric Providers and Hospital Administrators
- Less than 1 month of HEAR 4 Mamas experience if involved in the hospital where participants are recruited from.
- Unable or unwilling to commit to completing surveys or an interview.
- Speaking a language other than English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual Care
AIM (AIM Alliance for Innovation on Maternal Health) safety bundles delivered in-person
|
|
|
Experimental: Usual Care plus H.E.A.R. for Mamas
H.E.A.R. for Mamas is designed to provide the AIM (Alliance for Innovation on Maternal Health) Postpartum Discharge Transition education systematically and to frequently monitor women for signs and symptoms of postpartum complications using simple, patient-centered technology (text/phone).
|
H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emergency Department (ED) visits within six weeks postpartum
Time Frame: Within six weeks following the delivery
|
Percent of postpartum women with an ED visit that occurs within six weeks following delivery
|
Within six weeks following the delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Reported Outcomes (PROs)
Time Frame: time of study enrollment (baseline=0), and 3, 6, and 12 months postpartum
|
Secondary outcomes will include PROs which will be measured at the time of study enrollment (baseline=0), and 3, 6, and 12 months postpartum.
|
time of study enrollment (baseline=0), and 3, 6, and 12 months postpartum
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Social Determinants of Health (SDoH), Patient Activation, Shared Decision Making
Time Frame: HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum
|
SDoH will be measured by the Accountable Health Communities-Health-Related Social Needs (HRSN) and includes assessment of economic instability, low social support, food scarcity etc.
|
HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum
|
|
Patient Activation
Time Frame: HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum
|
Patient activation will be measured by the Patient Activation Measure (PAM-10).
|
HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum
|
|
Shared Decision Making
Time Frame: HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum
|
Perception of the shared decision-making process will be measured by Shared Decision-Making Questionnaire (SDM-Q-9).
|
HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00130902
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Complication
-
Herning HospitalCompleted
-
Riphah International UniversityRecruitingCombined Effects Of Stability Oriented Breathing Exercises and Kegel's Exercises in Postpartum WomenPostpartum Complication | StrengthPakistan
-
Riphah International UniversityRecruitingPostpartum ComplicationPakistan
-
Çankırı Karatekin UniversityCompletedPregnancy Related | Postpartum ComplicationTurkey (Türkiye)
-
KTO Karatay UniversityCompletedEpisiotomy | Episiotomy Wound | Postpartum Complication | Postpartum Recovery | Primiparous WomenTurkey (Türkiye)
-
Western Galilee Hospital-NahariyaNot yet recruitingPostpartum Hemorrhage | Postpartum Complication
-
University of ArkansasEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingPostpartum Complication | Health Care Seeking Behavior
-
Riphah International UniversityCompletedPostpartum ComplicationPakistan
-
The University of Hong KongQueen Mary Hospital, Hong KongNot yet recruitingMisoprostol | Delivery Complication | Primary Postpartum Hemorrhage
-
Necmettin Erbakan UniversityCompletedPostpartum Depression | Postnatal Complication | Nurse's RoleTurkey
Clinical Trials on H.E.A.R. for Mamas
-
Queen's University, BelfastCompletedAnxietyUnited Kingdom
-
Drexel UniversityUniversity of North Carolina, Chapel Hill; University of KwaZuluCompletedChlamydia | Gonorrhea | Human Immunodeficiency Virus | Trichomonas Vaginitis | Herpes Simplex Type IISouth Africa
-
King's College LondonAga Khan University; UK Research and Innovation; Centro Internacional para Saude...Completed
-
Tel Aviv UniversityEnrolling by invitation
-
EnnovaBio Australia Pharmaceuticals Pty LtdCompleted
-
ZYUS Life Sciences Inc.Novotech (Australia) Pty Limited; ZYUS Life Sciences Australia Pty LtdCompletedHealthy | OsteoarthritisAustralia
-
Theravance BiopharmaCompleted
-
The University of Hong KongUnknown
-
Region StockholmActive, not recruitingFamilial Hypertriglyceridemia
-
Lentechs, LLCCompletedPresbyopia | Astigmatism | Myopia | HyperopiaUnited States